The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Fatty Acid-binding Proteins Transport N-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid Transport Inhibitors
Open accessAbstract
N-acylethanolamines (NAEs) are bioactive lipids that engage diverse receptor systems. Recently, we identified fatty acid-binding proteins (FABPs) as intracellular NAE carriers. Here, we provide two new functions for FABPs in NAE signaling. We demonstrate that FABPs mediate the nuclear translocation of the NAE oleoylethanolamide, an agonist of nuclear peroxisome proliferator-activated receptor α (PPARα). Antagonism of FABP function through chemical inhibition, dominant-negative approaches, or shRNA-mediated knockdown reduced PPARα activation, confirming a requisite role for FABPs in this process. In addition, we show that NAE analogs, traditionally employed as inhibitors of the putative endocannabinoid transmembrane transporter, target FABPs. Support for the existence of the putative membrane transporter stems primarily from pharmacological inhibition of endocannabinoid uptake by such transport inhibitors, which are widely employed in endocannabinoid research despite lacking a known cellular target(s). Our approach adapted FABP-mediated PPARα signaling and employed in vitro binding, arachidonoyl-[1-(14)C]ethanolamide ([(14)C]AEA) uptake, and FABP knockdown to demonstrate that transport inhibitors exert their effects through inhibition of FABPs, thereby providing a molecular rationale for the underlying physiological effects of these compounds. Identification of FABPs as targets of transport inhibitors undermines the central pharmacological support for the existence of an endocannabinoid transmembrane transporter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007) · Cell · doi:10.1016/j.cell.2007.02.050 · Cited by 680
Tan, N.-S., Shaw, N. S., Vinckenbosch, N., Liu, P., Yasmin, R., Desvergne, B., Wahli, W., & Noy, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5114-5127.2002 · Cited by 499
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
The anandamide transport inhibitor AM404 activates vanilloid receptors
Zygmunt, P. M., Chuang, H.-H., Movahed, P., Julius, D., & Högestätt, E. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00207-7 · Cited by 270
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230 · cited 13×
“The prototypical transport inhibitors, OMDM1, OMDM2, VDM11, AM1172, and AM404 (12, 14, 15, 28), which reduce AEA uptake across multiple cell types, were employed.”
MethodInfluentialTRPV1 in Brain Is Involved in Acetaminophen-Induced Antinociception
Mallet, C., Barrière, D. A., Ermund, A., Jönsson, B. A. G., Eschalier, A., Zygmunt, P. M., & Högestätt, E. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012748 · Cited by 165
Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses
Kim, J., & Alger, B. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2517 · Cited by 149
La Rana, G., Russo, R., Campolongo, P., Bortolato, M., Mangieri, R. A., Cuomo, V., Iacono, A., Raso, G. M., Meli, R., Piomelli, D., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100792 · Cited by 97
La Rana, G., Russo, R., D'Agostino, G., Sasso, O., Raso, G. M., Iacono, A., Meli, R., Piomelli, D., & Calignano, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.021 · Cited by 42
Cited by
Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training
Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c110062 · Cited by 831
Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications
Carta, G., Murru, E., Banni, S., & Manca, C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00902 · Cited by 809
Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
Birkenfeld, A. L., & Shulman, G. I. (2014) · Hepatology · doi:10.1002/hep.26672 · Cited by 738
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J. M., Miyauchi, J. T., Tsirka, S. E., Ojima, I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618447 · Cited by 312
Self-citationTherapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Bioactive lipid mediators in skin inflammation and immunity
Kendall, A. C., & Nicolaou, A. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.10.003 · Cited by 229
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia
Kaczocha, M., Rebecchi, M. J., Ralph, B. P., Teng, Y.-H. G., Berger, W. T., Galbavy, W., Elmes, M. W., Glaser, S. T., Wang, L., Rizzo, R. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094200 · Cited by 142
Self-citationRole of the endocannabinoid system in the regulation of intestinal homeostasis
Cuddihey, H., MacNaughton, W. K., & Sharkey, K. A. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.05.015 · Cited by 79
Kaczocha, M., Glaser, S. T., Maher, T., Clavin, B., Hamilton, J., Rourke, J. O., Rebecchi, M., Puopolo, M., Owada, Y., & Thanos, P. K. (2015) · Molecular Pain · doi:10.1186/s12990-015-0056-8 · Cited by 68
Self-citation
Metadata
- Authors
- Kaczocha, M., Vivieca, S., Sun, J., Glaser, S. T., & Deutsch, D. G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 287
- Issue
- 5
- Pages
- 3415-3424
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2018780060
- Cited by
- 187
- References
- 10
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.